Advancing on AIDS


Sign up for our email newsletter for the latest science news

One quarter of all hiv carriers now harbor strains resistant to the most potent drug combinations on the market. But a new candidate called T-20 gives those drugs a lift by arresting the deadly virus before it can start infecting cells. Existing aids medications target the enzymes HIV uses to reproduce itself. T-20 works differently. It mimics a crucial, coiled protein molecule that hiv unhooks in order to get into a cell and infect it. T-20 blocks this entry point. "The host cell and the virus can't come close enough together to fuse," says biochemist Sam Hopkins of Trimeris Inc. in Durham, North Carolina, which is developing the drug. In 16-week clinical trials conducted on 55 patients--all of whom had exhausted other treatments--almost two thirds saw significant drops in the concentration of hiv in the blood. In many cases, the virus became undetectable. Researchers anticipate the drug will be generally available within two years and will work on viral strains impervious to existing aids medications. The main drawback is that T-20 is a protein, so it must be injected twice a day; if it were taken as a pill, it would be digested in the gut.

1 free article left
Want More? Get unlimited access for as low as $1.99/month

Already a subscriber?

Register or Log In

1 free articleSubscribe
Magazine Examples
Want more?

Keep reading for as low as $1.99!


Already a subscriber?

Register or Log In

More From Discover
Recommendations From Our Store
Shop Now
Stay Curious
Our List

Sign up for our weekly science updates.

To The Magazine

Save up to 70% off the cover price when you subscribe to Discover magazine.

Copyright © 2021 Kalmbach Media Co.